The central role of inflammation in atherosclerosis was further established by the CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcome Study), which demonstrated that targeted inhibition of IL-1β significantly reduced cardiovascular events 59-61. This evidence concerns the gene IL1B and deep vein thrombosis.